The Experts below are selected from a list of 27294 Experts worldwide ranked by ideXlab platform

James D Luketich - One of the best experts on this subject based on the ideXlab platform.

  • Radiofrequency Ablation for the treatment of non small cell lung cancer in marginal surgical candidates
    The Journal of Thoracic and Cardiovascular Surgery, 2005
    Co-Authors: Hiran C Fernando, Alberto De Hoyos, Rodney J Landreneau, Sebastian Gilbert, William E Gooding, Percival O Buenaventura, Neil A Christie, Chandra P Belani, James D Luketich
    Abstract:

    Objective Treatment options for patients with non–small cell lung cancer who are not surgical candidates or who refuse operation are limited. Radiofrequency Ablation represents a potential less invasive option for these patients. Our initial experience with Radiofrequency Ablation for peripheral, primary non–small cell lung cancer is reported. Methods We treated 21 tumors in 18 patients. Median age was 75 (range 58-86) years. Cancer stages were I (n = 9), II (n = 2), III (n = 3), and IV (n = 4). Patients with stage IV disease included 3 with recurrence after previous lobectomies and 1 with a synchronous liver metastasis also treated with Radiofrequency Ablation. Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency Ablation was delivered by minithoracotomy in 2 cases and by a computed tomography–guided percutaneous approach in 16 patients. Computed tomographic and positron emission tomographic scans were used to evaluate recurrence and radiographic response in ablated nodules. Results One postoperative death occurred from pneumonia after open Radiofrequency Ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter was required in 7 patients (38.9%) for procedure-related pneumothoraces. At a median follow-up of 14 months, 15 patients (83.3%) were alive. Local progression occurred in 8 nodules (38.1%). Mean and median progression-free intervals were 16.8 and 18 months, respectively. For stage I cancers, mean progression-free interval was 17.6 months. Median progression-free interval was not reached. Conclusion This study demonstrates the feasibility of Radiofrequency Ablation for small, peripheral non–small cell lung cancer tumors. Local control is comparable to, if not better than, that provided by radiotherapy. Radiofrequency Ablation should continue to be evaluated by thoracic surgeons as a noninvasive therapy for the high-risk patient with non–small cell lung cancer.

  • Radiofrequency Ablation identification of the ideal patient
    Clinical Lung Cancer, 2004
    Co-Authors: Hiran C Fernando, Alberto De Hoyos, Chandra P Belani, Virginia R Litle, James D Luketich
    Abstract:

    Abstract Radiofrequency (RF) Ablation (RFA) is a relatively new modality that is being used for lung tumors with increasing frequency. Radiofrequency energy consists of an alternating current that moves from an active electrode that is placed within the tumor to dispersive electrodes that are placed on the patient. As the RF energy is applied, frictional heating of tissues results, with cell death occurring at temperatures > 60°C. This article discusses preclinical and early clinical experience with RFA for lung tumors. Radiofrequency Ablation has been used for patients with primary lung cancer and limited pulmonary metastases. Current data suggest that RFA is most suitable for tumors ≤ 4 cm in size and is better for peripheral rather than centrally based nodules. Additionally, studies of RFA followed by resection have demonstrated a learning-curve effect with improved tumor kill in the later cases performed in these series. Surgical resection should continue to be the primary modality offered to patients with early-stage non–small-cell lung cancer and limited metastatic disease to the lungs (when the primary tumor is controlled). Radiofrequency Ablation is a good option for those patients who are believed to be at increased risk for resection or who refuse resection, when operation would otherwise be appropriate therapy. Additionally, RFA may be used for local control of peripheral tumors in patients with more advanced cancers in combination with other therapies.

Kaori Togashi - One of the best experts on this subject based on the ideXlab platform.

Hiran C Fernando - One of the best experts on this subject based on the ideXlab platform.

  • Radiofrequency Ablation for the treatment of non small cell lung cancer in marginal surgical candidates
    The Journal of Thoracic and Cardiovascular Surgery, 2005
    Co-Authors: Hiran C Fernando, Alberto De Hoyos, Rodney J Landreneau, Sebastian Gilbert, William E Gooding, Percival O Buenaventura, Neil A Christie, Chandra P Belani, James D Luketich
    Abstract:

    Objective Treatment options for patients with non–small cell lung cancer who are not surgical candidates or who refuse operation are limited. Radiofrequency Ablation represents a potential less invasive option for these patients. Our initial experience with Radiofrequency Ablation for peripheral, primary non–small cell lung cancer is reported. Methods We treated 21 tumors in 18 patients. Median age was 75 (range 58-86) years. Cancer stages were I (n = 9), II (n = 2), III (n = 3), and IV (n = 4). Patients with stage IV disease included 3 with recurrence after previous lobectomies and 1 with a synchronous liver metastasis also treated with Radiofrequency Ablation. Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency Ablation was delivered by minithoracotomy in 2 cases and by a computed tomography–guided percutaneous approach in 16 patients. Computed tomographic and positron emission tomographic scans were used to evaluate recurrence and radiographic response in ablated nodules. Results One postoperative death occurred from pneumonia after open Radiofrequency Ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter was required in 7 patients (38.9%) for procedure-related pneumothoraces. At a median follow-up of 14 months, 15 patients (83.3%) were alive. Local progression occurred in 8 nodules (38.1%). Mean and median progression-free intervals were 16.8 and 18 months, respectively. For stage I cancers, mean progression-free interval was 17.6 months. Median progression-free interval was not reached. Conclusion This study demonstrates the feasibility of Radiofrequency Ablation for small, peripheral non–small cell lung cancer tumors. Local control is comparable to, if not better than, that provided by radiotherapy. Radiofrequency Ablation should continue to be evaluated by thoracic surgeons as a noninvasive therapy for the high-risk patient with non–small cell lung cancer.

  • Radiofrequency Ablation identification of the ideal patient
    Clinical Lung Cancer, 2004
    Co-Authors: Hiran C Fernando, Alberto De Hoyos, Chandra P Belani, Virginia R Litle, James D Luketich
    Abstract:

    Abstract Radiofrequency (RF) Ablation (RFA) is a relatively new modality that is being used for lung tumors with increasing frequency. Radiofrequency energy consists of an alternating current that moves from an active electrode that is placed within the tumor to dispersive electrodes that are placed on the patient. As the RF energy is applied, frictional heating of tissues results, with cell death occurring at temperatures > 60°C. This article discusses preclinical and early clinical experience with RFA for lung tumors. Radiofrequency Ablation has been used for patients with primary lung cancer and limited pulmonary metastases. Current data suggest that RFA is most suitable for tumors ≤ 4 cm in size and is better for peripheral rather than centrally based nodules. Additionally, studies of RFA followed by resection have demonstrated a learning-curve effect with improved tumor kill in the later cases performed in these series. Surgical resection should continue to be the primary modality offered to patients with early-stage non–small-cell lung cancer and limited metastatic disease to the lungs (when the primary tumor is controlled). Radiofrequency Ablation is a good option for those patients who are believed to be at increased risk for resection or who refuse resection, when operation would otherwise be appropriate therapy. Additionally, RFA may be used for local control of peripheral tumors in patients with more advanced cancers in combination with other therapies.

Toshiya Shibata - One of the best experts on this subject based on the ideXlab platform.

A R Gillams - One of the best experts on this subject based on the ideXlab platform.

  • outcome after Radiofrequency Ablation of sarcoma lung metastases
    CardioVascular and Interventional Radiology, 2014
    Co-Authors: Claus Koelblinger, Sandra J Strauss, A R Gillams
    Abstract:

    Purpose Resection is the mainstay of management in patients with sarcoma lung metastases, but there is a limit to how many resections can be performed. Some patients with inoperable disease have small-volume lung metastases that are amenable to thermal Ablation. We report our results after Radiofrequency Ablation (RFA).